Science & technology
Our pipeline
RSV

RSV investigational vaccines

Paused developmental vaccine candidates
Respiratory syncytial virus (RSV) Vaccine Details
Therapeutic area
Infectious disease
Status
Technology
Respiratory diseases
Respiratory syncytial virus (RSV)
 
Phase 3†
Infants via maternal immunization*
Respiratory diseases
Respiratory syncytial virus (RSV)
 
Phase 1
Children between 2−6 years old
Respiratory diseases
Respiratory syncytial virus (RSV)
 
Phase 1
Adults 60+ years old*
Matrix-M™ adjuvant
Therapeutic area
Respiratory diseases
Infectious disease
Respiratory syncytial virus (RSV)
Status
 
Phase 3†
Infants via maternal immunization*
Technology
Status
 
Phase 1
Children between 2−6 years old
Technology
Status
 
Phase 1
Adults 60+ years old*
Technology
Matrix-M™ adjuvant

About the candidates

RSV fusion (RSV F) recombinant protein nanoparticle investigational vaccines with or without aluminum phosphate or Matrix-M™ as an adjuvant.

Why it matters

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection and hospitalization in infants, young children, and older adults worldwide, causing over 3.2 million hospitalizations in children and 336,000 hospitalizations in adults ≥65 years of age.1,2 The development of RSV vaccines has been identified as a priority for WHO's Vaccine Product and Delivery Research Unit.3

†This trial did not meet its primary endpoint.
  1. Verwey C, Nunes M. Lancet Glob Health. 2020;8:1247–1248.
  2. Shi T, et al. J Infect Dis.. 2020;222:577–583.
  3. Respiratory Syncytial Virus (RSV). WHO. Available at: https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/respiratory-syncytial-virus-(rsv) [Accessed 3 Sept 2021].
Clinical trials
More about the disease